Expedited Vaccine Technology Transfer is Key in COVID-19 Battle, an Industrial Info Market Brief
Expedited Vaccine Technology Transfer is Key in COVID-19 Battle, an Industrial Info Market Brief
Attachment: Map
The U.S. government has chosen three vaccine candidates to fund Phase 3 trials under Operation Warp Speed: Moderna's mRNA-1273, the University of Oxford and AstraZeneca's AZD1222, and Pfizer and BioNTech's BNT162. For any of these vaccines to be feasible in "Warp Speed" time, technology transfer (moving the knowledge about and the ability to produce a vaccine from development to manufacturing) has to be carefully and accurately expedited.
Subscribe Now!(All Fields Required)
Related Articles
Articles related to this company
- France Plans $55 Billion in Windfarms as Offshore Projects Gain Momentum
- Africa's Fertilizer Demand Sparks $5.8 Billion of Projects
- Poland's PGE Plans $7 Billion Renewable Energy Push
- Peru's Runoff Presidential Election Could Impact $45 Billion in Mining Proj...
- Industrial Construction Activity Up 37% So Far in 2021